Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

August 11, 2022
Natera Announces Enrollment Completion for RenaCARE Study
RenaCARE Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease AUSTIN, Texas , Aug. 11, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight
August 10, 2022
Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
AUSTIN, Texas , Aug. 10, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama®
August 4, 2022
Natera Reports Second Quarter 2022 Financial Results
AUSTIN, Texas , Aug. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent business progress and financial outlook.
August 1, 2022
Natera Announces Second Quarter 2022 Earnings Conference Call
AUSTIN, Texas , Aug. 1, 2022 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2022 , after the market close on August 4, 2022. Natera will host a conference call and webcast
July 18, 2022
Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents
AUSTIN, Texas , July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's   September 2021 decision that all three CareDx patents

Upcoming Events

More events are coming soon.

Past events